Infliximab injections for severe ulcerative colitis
Part of Digestive system clinical trials.
This study looks at how well a subcutaneous (under-the-skin) form of infliximab works for people with acute severe ulcerative colitis, after they've had initial treatment with the intravenous (IV) form. It may help doctors understand if switching to injections is a good option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with acute severe ulcerative colitis based on specific criteria.
- You have received at least one injection of infliximab under the skin after starting with two or three IV infusions.
- You have been followed for at least 12 months after your first injection.
- Your medical records have 12 months of data available.
- You are not currently taking infliximab as a maintenance IV treatment.
- You did not switch from IV to injection after more than three IV infusions.
- You are not a protected person (e.g., under guardianship or in a vulnerable situation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if switching from a high-dose infliximab IV infusion to a daily or weekly injection under the skin works just as well. It is for people with inflammatory bowel disease who are already stable on IV infliximab.
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
This study tracks how patients with Crohn's disease or ulcerative colitis respond to infliximab (a biologic medication) given as injections under the skin after an initial IV dose. Researchers want to understand which patients benefit most and for how long.
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
This trial uses a computer model to study how the body processes infliximab (a medicine that reduces inflammation) in people with Crohn's disease or ulcerative colitis. It aims to find the best dose to help control symptoms.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.